Back
Speaker illustration

Doctor Amit Khera

Verve Therapeutics, Boston (United States of America)

Presentations

An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

Event: ESC Congress 2023

Topic: Drug therapy

Session: What's new in lipid lowering?

Access
Like
Thumbnail

An in vivo CRISPR base editing therapy to inactivate the ANGPTL3 gene: nomination of a development candidate for VERVE-201

Event: ESC Congress 2022

Topic: Gene Therapy, Cell Therapy

Session: RNA and gene therapy of vascular diseases

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources